These mechanistic data suggest a clinical pharmacologic strategy to counter the aggressive disease and poor clinical outcomes conferred by inheritance of the adrenal-permissive HSD3B1 allele, which commonly occurs in men with prostate cancer. This evidence concerns the gene HSD3B1 and prostate carcinoma.